LG Chem partners with UK's LabGenius on AI cancer drugs

LG Chem said Thursday it signed a joint research and license option agreement with UK-based biotechnology company LabGenius Therapeutics to develop next-generation multispecific antibody therapies for cancer using artificial intelligence.

LabGenius has developed EVA, an AI-powered drug discovery platform that combines machine learning with automated high-throughput experimentation to design and optimize therapeutic antibodies.

Under the agreement, LG Chem will provide an upfront payment and rese ...